RNA
Avidity Biosciences
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Atrium Therapeutics received FDA IND clearance for ATR 1072 in PRKAG2 syndromeJul 14, 2026
- Avidity Biosciences' Del-zota demonstrated reversal of disease progression across key functional endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 trial in people living with DMD44Sep 10, 2025
- Avidity Biosciences announces completion of enrollment for HARBOR™, the first global Phase 3 trial of Delpacibart Etedesiran (del-desiran) for treatment of DM1, and provides regulatory submission guidanceJul 28, 2025
- Avidity Biosciences receives FDA Breakthrough Therapy designation for Delpacibart Zotadirsen (del-zota) to treat Duchenne muscular dystrophy in patients with exon 44 skipping mutationsJul 23, 2025
- Avidity Biosciences to present topline results from Phase 1/2 FORTITUDE™ trial in FSHD at upcoming international research congressJun 12, 2025